AbbVie Inc., a biopharmaceutical company, has filed its Specialized Disclosure Report (Form SD) with the U.S. Securities and Exchange Commission (SEC) for the reporting period from January 1 to December 31, 2023. The report, which is required under Rule 13p-1 of the Securities Exchange Act, includes the company's Conflict Minerals Report as Exhibit 1.01. This report details AbbVie's due diligence regarding the source and chain of custody of conflict minerals used in their products. The Conflict Minerals Report is also available on AbbVie's investor relations website. The filing, signed by Scott T. Reents on May 31, 2024, does not apply to the Resource Extraction Issuer Disclosure, which is not applicable to the company.

AbbVie Inc., a biopharmaceutical company, has filed its Specialized Disclosure Report (Form SD) with the U.S. Securities and Exchange Commission (SEC) for the reporting period from January 1 to December 31, 2023. The report, which is required under Rule 13p-1 of the Securities Exchange Act, includes the company's Conflict Minerals Report as Exhibit 1.01. This report details AbbVie's due diligence regarding the source and chain of custody of conflict minerals used in their products. The Conflict Minerals Report is also available on AbbVie's investor relations website. The filing, signed by Scott T. Reents on May 31, 2024, does not apply to the Resource Extraction Issuer Disclosure, which is not applicable to the company.